Penumbra, Inc. $PEN Shares Sold by Strs Ohio

Strs Ohio lessened its holdings in Penumbra, Inc. (NYSE:PEN) by 16.2% during the 1st quarter, Holdings Channel reports. The firm owned 10,306 shares of the company’s stock after selling 1,990 shares during the quarter. Strs Ohio’s holdings in Penumbra were worth $3,384,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of PEN. Geode Capital Management LLC raised its position in shares of Penumbra by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 766,510 shares of the company’s stock worth $238,365,000 after purchasing an additional 18,738 shares during the last quarter. Invesco Ltd. lifted its stake in Penumbra by 1.1% in the 4th quarter. Invesco Ltd. now owns 638,305 shares of the company’s stock valued at $198,455,000 after buying an additional 7,211 shares in the last quarter. Artisan Partners Limited Partnership grew its holdings in Penumbra by 165.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 594,112 shares of the company’s stock valued at $184,715,000 after buying an additional 370,636 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Penumbra by 1.5% during the 4th quarter. Janus Henderson Group PLC now owns 475,898 shares of the company’s stock valued at $147,962,000 after buying an additional 7,050 shares during the last quarter. Finally, Capital World Investors increased its position in Penumbra by 2.6% during the fourth quarter. Capital World Investors now owns 426,456 shares of the company’s stock worth $132,589,000 after buying an additional 10,724 shares in the last quarter. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Penumbra Trading Up 0.3%

PEN traded up $0.85 during trading on Tuesday, hitting $319.08. The company’s stock had a trading volume of 46,218 shares, compared to its average volume of 733,928. Penumbra, Inc. has a twelve month low of $221.26 and a twelve month high of $362.41. The stock has a market cap of $12.55 billion, a PE ratio of 73.56, a PEG ratio of 1.97 and a beta of 0.70. The firm’s 50 day moving average price is $321.32 and its 200-day moving average price is $329.68. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.02 and a quick ratio of 3.95.

Penumbra (NYSE:PEN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by ($0.24). The business had revenue of $374.76 million for the quarter, compared to analyst estimates of $370.47 million. Penumbra had a return on equity of 10.87% and a net margin of 11.76%.Penumbra’s revenue for the quarter was up 15.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.83 EPS. On average, analysts expect that Penumbra, Inc. will post 5.04 earnings per share for the current year.

Analysts Set New Price Targets

PEN has been the subject of a number of analyst reports. Citigroup cut their price target on Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a report on Thursday, May 7th. Evercore reaffirmed an “outperform” rating and set a $320.00 price objective on shares of Penumbra in a research note on Monday. Royal Bank Of Canada reiterated a “sector perform” rating and set a $374.00 price objective on shares of Penumbra in a research report on Thursday, June 11th. Wall Street Zen raised shares of Penumbra to a “hold” rating in a research note on Saturday, May 9th. Finally, Zacks Research lowered shares of Penumbra from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Three investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $360.33.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.